Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GRI, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Active Comparator: 6.0mg GRI-0621 | Chronic Liver Disease | Phase 2 · NCT02949375 | Terminated |
Also used in these trials (approved or third-party drugs, not GRI's own candidates): Tazarotene.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
GRI holds $10.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations, an estimated runway of 12.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 58 · Elevated
Therefore, there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| MJL Manager LLC | Institution (13G, 5%+) | 159,378 | 7.29% | 2026-11-05 |
Share count 2,186,115 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →